https://www.businesswire.com/news/home/20200528005275/en/Ashvattha-Therapeutics-Subsidiary-Orpheris-Announces-FDA-Agreement
0
0
Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients
5/28/20 at 5:10am
Organization
Business Wire
Authors
Details
45 words
Summarize
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ashvattha Therapeutics Subsidiary Orpheris Announces FDA Agreement to Initiate Phase 2 Study Evaluating OP-101 in Severe COVID-19 Patients
Create an account or login to join the discussion